Market Tracker

12/15 5:15pm ET

Clovis Oncology Inc (NASDAQ:CLVS)

64.13
Delayed Data
As of Dec 15
 0.00 / 0.00%
Today’s Change
35.82
Today|||52-Week Range
99.45
+44.37%
Year-to-Date
Value Biotech ETFs to Buy Now
Dec 13 / Zacks.com - Paid Partner Content
Clovis' sNDA for Rubraca Gets Priority Review in the U.S.
Dec 06 / Zacks.com - Paid Partner Content
Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study
Dec 11 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data
Dec 06 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close64.13
Today’s open64.08
Day’s range63.00 - 65.40
Volume2,027,652
Average volume (3 months)1,393,750
Market cap$3.1B
Data as of 4:00pm ET, 12/15/2017

Growth & Valuation

Earnings growth (last year)+7.35%
Earnings growth (this year)+15.91%
Earnings growth (next 5 years)-71.23%
Revenue growth (last year)--
P/E ratioNM
Price/Sales21,912.70
Price/Book--

Competitors

 Today’s
change
Today’s
% change
PTLAPortola Pharmaceutic...0.000.00%
OPKOPKO Health Inc0.000.00%
PBYIPuma Biotechnology I...0.000.00%
MNKMallinckrodt Plc0.000.00%
Data as of 4:01pm ET, 12/15/2017

Financials

Next reporting dateMarch 1, 2018
EPS forecast (this quarter)-$1.28
Annual revenue (last year)$78.0K
Annual profit (last year)-$349.1M
Net profit margin-447,611.54%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Patrick J. Mahaffy
Principal Financial Officer &
SVP-Finance
Daniel W. Muehl
Corporate headquarters
Boulder, Colorado

Forecasts